osmotica pharmaceutical is focused on drug delivery technologies with a special focus in neurology-based therapies. we have a portfolio of products in various stages of development focused on the treatment of movement disorders, such as ms and parkinson's disease. in addition, we utilize our well-established drug delivery technologies (including our osmodex technologies) and our expertise to develop drug candidates for partner companies.
Company profile
Ticker
RVLPQ, RVLPQ
Exchange
Website
CEO
Brian A. Markison
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Osmotica Pharmaceuticals Ltd, Osmotica Pharmaceuticals plc
SEC CIK
Corporate docs
Subsidiaries
RVL Holdings US LLC • Osmotica Kereskedelmi es Szolgaltato Kft • RVL Finance Limited • Osmotica Pharmaceutical Corp. • RVL Pharmaceuticals, Inc. • Osmotica Argentina, S.A. • Valkyrie Group Holdings, Inc. • RVL Pharmacy, LLC ...
RVLPQ stock data
Latest filings (excl ownership)
8-K
Other Events
13 Feb 24
8-K
Other Events
17 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
20 Dec 23
8-K
Bankruptcy or Receivership
27 Nov 23
25-NSE
Exchange delisting
20 Nov 23
DEF 14A
Definitive proxy
16 Nov 23
PRE 14A
Preliminary proxy
6 Nov 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Entry into a Material Definitive Agreement
20 Oct 23
8-K
Termination of a Material Definitive Agreement
13 Oct 23
Transcripts
RVLPQ
Earnings call transcript
2023 Q2
14 Aug 23
RVLPQ
Earnings call transcript
2023 Q1
11 May 23
RVLPQ
Earnings call transcript
2022 Q4
20 Mar 23
RVLPQ
Earnings call transcript
2022 Q3
11 Nov 22
RVLPQ
Earnings call transcript
2022 Q2
11 Aug 22
RVLPQ
Earnings call transcript
2022 Q1
12 May 22
RVLPQ
Earnings call transcript
2021 Q4
30 Mar 22
RVLPQ
Earnings call transcript
2021 Q3
16 Nov 21
RVLPQ
Earnings call transcript
2021 Q2
17 Aug 21
RVLPQ
Earnings call transcript
2021 Q1
14 May 21
Latest ownership filings
SC 13D/A
Athyrium Opportunities IV Acquisition 2 LP
27 Nov 23
SC 13D/A
Altchem Ltd
1 Nov 23
4
Change in insider ownership
23 Oct 23
4
Change in insider ownership
23 Oct 23
4
Change in insider ownership
20 Oct 23
4
Change in insider ownership
20 Oct 23
144
Notice of proposed sale of securities
18 Oct 23
SC 13D/A
Athyrium Opportunities IV Acquisition 2 LP
13 Oct 23
144
Notice of proposed sale of securities
25 Sep 23
SC 13D
Athyrium Opportunities IV Acquisition 2 LP
5 Sep 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm | 19.16 mm |
Cash burn (monthly) | 4.49 mm | 687.83 k | 8.00 mm | 6.21 mm | 4.02 mm | 3.70 mm |
Cash used (since last report) | 45.62 mm | 6.98 mm | 81.23 mm | 63.02 mm | 40.82 mm | 37.57 mm |
Cash remaining | -26.46 mm | 12.18 mm | -62.07 mm | -43.86 mm | -21.66 mm | -18.41 mm |
Runway (months of cash) | -5.9 | 17.7 | -7.8 | -7.1 | -5.4 | -5.0 |
Institutional ownership, Q3 2023
71.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 8 |
Closed positions | 13 |
Increased positions | 8 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.56 bn |
Total shares | 80.09 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Avista Capital Partners III GP | 23.73 mm | $37.73 mm |
Altchem | 23.67 mm | $48.52 mm |
Athyrium Capital Management | 14.60 mm | $1.26 bn |
Athyrium Opportunities IV Acquisition 2 | 14.60 mm | $0.00 |
Renaissance Technologies | 1.08 mm | $93.00 k |
BX Blackstone | 632.26 k | $56.90 mm |
Geode Capital Management | 307.27 k | $26.61 mm |
Millennium Management | 272.58 k | $23.61 mm |
Vanguard | 246.35 k | $21.33 mm |
BLK Blackrock | 225.73 k | $19.55 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Oct 23 | Altchem | Ordinary Shares | Sell | Dispose S | No | No | 0.0312 | 4,758,899 | 148.48 k | 4,941,101 |
20 Oct 23 | Foundation Harsaul | Ordinary Shares | Sell | Dispose S | Yes | No | 0.0312 | 4,758,899 | 148.48 k | 4,941,101 |
19 Oct 23 | Altchem | Ordinary Shares | Sell | Dispose S | No | No | 0.0461 | 9,363,760 | 431.67 k | 9,700,000 |
19 Oct 23 | Foundation Harsaul | Ordinary Shares | Sell | Dispose S | Yes | No | 0.0461 | 9,363,760 | 431.67 k | 9,700,000 |
18 Oct 23 | Altchem | Ordinary Shares | Sell | Dispose S | No | No | 0.0646 | 3,421,537 | 221.03 k | 19,063,760 |
18 Oct 23 | Foundation Harsaul | Ordinary Shares | Sell | Dispose S | Yes | No | 0.0646 | 3,421,537 | 221.03 k | 19,063,760 |
15 Aug 23 | Avista Healthcare Partners GP | Ordinary Shares | Other | Dispose J | Yes | No | 0 | 23,730,864 | 0.00 | 0 |